Topic
What should I know about Saxenda, Victoza and generic liraglutide?
Victoza, Saxenda and the generics: the daily GLP-1s and the cheapest branded route.
Generic Liraglutide: The Cheapest Real GLP-1 in the USLiraglutide is the only GLP-1 receptor agonist with FDA-approved generics in the United States, for both diabetes and weight loss. Who makes them, what they cost, why a generic Victoza is not a generic Saxenda, and where supply stands in September 2026.Liraglutide FAQ: Victoza, Saxenda and the Generics, AnsweredPlain answers about liraglutide: what it is, how Victoza and Saxenda differ, which generics exist and what they cost, how it is dosed and stored, what the warnings say, and why some people still choose a daily GLP-1 over a weekly one.Saxenda Side Effects and Results: What the Label and Trials ShowHow much weight people actually lost on liraglutide 3 mg in the trials behind Saxenda's approval, how common nausea and vomiting really are, what the label's 16-week stopping rule means, and what happens after you stop.Saxenda vs Wegovy: How the Daily and Weekly Shots Really CompareSaxenda is daily liraglutide; Wegovy is weekly semaglutide. A head-to-head trial put average weight loss at 6.4% versus 15.8%. Here is what that means in practice, plus cost, side effects, and why Saxenda is being discontinued in 2027.Switching From Liraglutide to a Weekly GLP-1: What the Labels Actually SayThere is no official conversion chart from Saxenda or Victoza to Wegovy, Ozempic or Zepbound. Here is what the FDA labels do say about starting doses, overlapping GLP-1 drugs and shortages, plus the one study that tested a direct switch.Victoza vs Ozempic: The Daily and Weekly Diabetes Shots ComparedVictoza is daily liraglutide; Ozempic is weekly semaglutide. Both lower A1C and both cut cardiovascular risk in large outcome trials. The head-to-head data, the heart evidence, the price gap now that Victoza has generics, and what the labels actually say.Who Still Uses Liraglutide in 2026, and WhySemaglutide and tirzepatide beat liraglutide in every head-to-head. Yet about 47,000 Medicare beneficiaries filled generic liraglutide in 2025. Coverage, cash price, pediatric labeling and tolerability explain why the old daily shot has not gone away.